Assessment of Retinoblastoma Capacity in the Middle East, North Africa, and West Asia Region

Michala Burges, BS1,2; Ibrahim Qaddoumi, MD, MS1,3; Rachel C. Brennan, MD3; Lisa Krull, BS1; Natasha Sahr, PhD4; Carlos Rodriguez-Galindo, MD1,3; Sima Jeha, MD1,3; and Matthew W. Wilson, MD2,5

PURPOSE We aimed to evaluate the capacity to treat retinoblastoma in the Middle East, North Africa, and West Asia region.

METHODS A Web-based assessment that investigated retinoblastoma-related pediatric oncology and ophthalmology infrastructure and associated capacity at member institutions of the Pediatric Oncology East and Mediterranean group was distributed. Data were analyzed in terms of availability, location, and confidence of use for each resource needed for the management of retinoblastoma. Resources were categorized by diagnostics, focal therapy, chemotherapy, advanced treatment, and supportive care. Responding institutions were further divided into an asset-based tiered system.

RESULTS In total, responses from 23 institutions were obtained. Fifteen institutions reported the availability of an ophthalmologist, 12 of which held primary off-site appointments. All institutions reported the availability of a pediatric oncologist and systemic chemotherapy. A significant portion of available resources was located off site. Green laser was available on site at seven institutions, diode laser at six institutions, cryotherapy at 12 institutions, and brachytherapy at nine institutions. There existed marked disparity between the availability of some specific ophthalmic resources and oncologic resources.

CONCLUSION The assessment revealed common themes related to the treatment of retinoblastoma in low- and middle-income countries, including decentralization of care, limited resources, and lack of multidisciplinary care. Resource disparities warrant targeted intervention in the Middle East, North Africa, and West Asia region to advance the management of retinoblastoma in the region.

JCO Global Oncol 6:1531-1539. © 2020 by American Society of Clinical Oncology

INTRODUCTION Retinoblastoma is a rare intraocular malignancy; however, > 8,000 children are diagnosed every year worldwide with this neoplasm.1 In developed and high-middle-income countries, early recognition of disease, highly specific ophthalmic and oncologic resources, and strong multidisciplinary teams have led to > 90% survival.1-3 However, in low- and middle-income countries (LMICs), late diagnosis, limited accessibility, lack of treatment-specific resources, and poor compliance result in survival rates < 40%.2,4 More than 80% of the estimated 160,000 children with pediatric cancer reside in developing countries; therefore, more children die of retinoblastoma than survive globally.5,6 The disproportionate burden of disease motivates the need to improve retinoblastoma survival in LMICs.

Multidisciplinary care is integral to successful management of retinoblastoma. Pediatric oncologists, pathologists, and radiation oncologists, as well as basic diagnostics and a therapeutic infrastructure, are inherent cancer center components. However, ophthalmology is a restricted global resource with limited availability, further reduced when subspecialty training (ocular oncology) is considered.9 Ophthalmic infrastructure, including cryotherapy, laser therapy, fundus camera, and options for locally delivered chemotherapy, is linked with high equipment costs. Thus, the treatment of retinoblastoma necessitates the acquisition of both personnel and equipment that extend beyond basic pediatric cancer care.

The Pediatric Oncology East and Mediterranean (POEM) group is a collaborative platform established in 2013 for health care professionals from pediatric oncology centers in 28 countries in the Middle East, North Africa, and West Asia region. The goal of the group is to share experience and establish common strategies to optimize the care of pediatric oncology patients. Working with POEM, we conducted the first
CONTEXT

Key Objective
What is the retinoblastoma-specific capacity of institutions belonging to the Middle East, North Africa, and West Asia region in terms of ophthalmic and oncologic resources?

Knowledge Generated
The assessment revealed disparity between ophthalmic and general oncology resources, allowing us to separate respondent institutions into an asset-based classification system. The majority of institutions belonged to the middle tier (tier 2), which requires the capacity to treat disease by enucleation with limited option for eye-sparing therapy as a result of lack of focal modalities.

Relevance
To our knowledge, this is the first assessment of its kind, one dedicated to the capacity to treat a rare pediatric cancer that requires highly specialized resources. With knowledge of resource capacity and subsequent institution classification, an informed referral network and strategy can be designed for the region. In addition, this methodology can serve as a model for survey examination of other rare pediatric cancers that similarly require highly specialized resources.

assessments of relevant retinoblastoma-related treatment capacity in the Eastern Mediterranean region. This comprehensive needs assessment is a crucial first step in improving global survival of retinoblastoma by developing targeted, regional strategies for disease management.

METHODS

A Web-based assessment (SurveyMonkey, San Mateo, CA) that investigated retinoblastoma-related pediatric oncology and ophthalmology infrastructure was developed with expert review by an ophthalmologist and three pediatric oncologists with experience in the management of patients with retinoblastoma. Concern for self-reported outcomes bias was identified, and the survey was refined to focus explicitly on resource infrastructure.

A Web link was distributed to representatives from POEM member institutions (n = 72). There were 15 questions in total, eight of which had multiple components. Availability, on-site/off-site location, and confidence of use were examined for 30 resources via the eight multiple-component questions. Three reminder e-mails were sent requesting the completion of the assessment from June to September 2018. Respondents were required to answer every question from a drop-down menu before submission to mitigate response bias.

Resources were grouped into the following categories: human resources, diagnostics, and treatment modalities. A range from general oncology to highly specific retinoblastoma treatment modalities was delineated (Tables 1 and 2) to evaluate centralization of care, training opportunities, and the availability of resources across the region.

Respondent institutions were categorized into an asset-based tier classification system based on availability of ophthalmic recourses that was aided in part by the International Society of Pediatric Oncology – Pediatric Oncology in Developing Countries guidelines for retinoblastoma. Tier 1 did not have access to an ophthalmologist to treat retinoblastoma. Tier 2 had access to an ophthalmologist. Tier 2 had access to enucleation, chemotherapy, and ophthalmic pathology, but a lack of focal treatment modalities limited opportunities for ocular salvage. Tier 3 had access to enucleation and eye-sparing therapies for treatment of intraocular disease, including access to most focal therapies.

Descriptive statistics (frequency and percentage) were reported for survey questions. The Cochran-Armitage trend test was used to assess the association between institutional ophthalmic and basic oncologic resources (no or yes and available or not available) and institutional tier classification (tiers 1, 2, and 3). Exact $P$ values were reported for these associations. $P$ values were adjusted for multiple testing but are not reported. We also explored the association between institutional ophthalmic and basic oncologic resources and institutional tier classification adjusting for gross domestic product (GDP) using analysis of covariance and logistic regression. These analyses revealed no impact of GDP and therefore provide no additional information. Therefore, we only report on the bivariate associations. Statistical analyses were conducted using SAS software version 9.4 (SAS Institute, Cary, NC). A two-sided significance level of $P < .05$ was considered statistically significant.

RESULTS

The needs assessment survey was sent via Web link to 72 POEM-affiliated institutions, with 27 respondents. Four respondents were excluded (two submissions had no survey question responses, and two were duplicate responses from the same institution). In the duplicate cases, the most complete response was selected from each institution. Twenty-one of 23 analyzed responses were complete; two respondents submitted incomplete forms as a result of a system error. The 23 respondents represent 15 countries and 32.0% of the POEM member institutions at
According to the World Bank income level classification, one respondent belongs to a high-income country, eight respondents belong to upper-middle–income countries, 12 respondents belong to lower-middle–income countries, and two respondents belong to low-income countries.8

Key personnel were reported, including those with primary off-site appointments, which indicates the time and effort of the provider were divided between two or more institutions as a consulting service. Pediatric oncologists were present at all 23 institutions, five (21.7%) of which held primary off-site appointments. Pathologists were available at 20 (87.0%) institutions, six (30.0%) of which held primary off-site appointments. Radiation oncologists were present at 17 (73.9%) institutions, nine (52.9%) of which held primary off-site appointments. Ophthalmologists were

### TABLE 1. Pediatric Oncology Resources, Availability, and Confidence of Use

| Resource                        | Available or Limited Availability | On-Site Availability | Confident Use |
|---------------------------------|-----------------------------------|----------------------|---------------|
| **Diagnostics**                 |                                   |                      |               |
| MRI                             | 22/23 (95.7)                      | 18/22 (81.8)         | 17/22 (77.3)  |
| Lumbar puncture                 | 23/23 (100.0)                     | 23/23 (100.0)        | 19/23 (82.6)  |
| Bone marrow aspiration          | 23/23 (100.0)                     | 23/23 (100.0)        | 19/23 (82.6)  |
| CSF cytospin                    | 21/23 (91.3)                      | 19/21 (90.5)         | 18/21 (85.7)  |
| Genetic testing                 | 11/23 (47.8)                      | 1/11 (9.1)           | 1/11 (9.1)    |
| **Chemotherapy**                |                                   |                      |               |
| Systemic                       | 22/23 (95.7)                      | 22/22 (100.0)        | 18/22 (81.8)  |
| **Treatment of advanced disease** |                                 |                      |               |
| EBRT                            | 18/23 (78.3)                      | 12/18 (66.7)         | 16/18 (88.9)  |
| High-dose chemotherapy          | 20/23 (87.0)                      | 19/20 (95.0)         | 12/20 (60.0)  |
| BMT                             | 14/23 (60.9)                      | 9/14 (64.3)          | 6/14 (42.9)   |
| ASCR                            | 16/23 (69.6)                      | 9/16 (56.3)          | 7/16 (43.8)   |
| Abbreviations: ASCR, autologous stem-cell rescue; BMT, bone marrow transplantation; CSF, cerebrospinal fluid; EBRT, external-beam radiation therapy; MRI, magnetic resonance imaging.

### TABLE 2. Ophthalmic Resources Availability, Location, and Confidence of Use

| Resource                        | Available or Limited Availability | On-Site Availability | Confident Use |
|---------------------------------|-----------------------------------|----------------------|---------------|
| **Diagnostics**                 |                                   |                      |               |
| EUA                             | 21/23 (91.3)                      | 11/21 (52.4)         | 16/21 (76.2)  |
| Fundus camera                   | 17/23 (73.9)                      | 8/17 (47.1)          | 10/17 (58.8)  |
| Ocular ultrasound              | 20/23 (87.0)                      | 10/20 (50.0)         | 13/20 (65.0)  |
| Indirect ophthalmoscope        | 21/23 (91.3)                      | 13/21 (61.9)         | 16/21 (76.2)  |
| Pathology for enucleated eye    | 22/23 (95.7)                      | 18/22 (81.8)         | 14/22 (63.6)  |
| **Chemotherapy**                |                                   |                      |               |
| Intra-arterial                  | 6/23 (26.1)                       | 5/6 (83.3)           | 3/6 (50.0)    |
| Intravitreal                    | 12/23 (52.2)                      | 7/12 (58.3)          | 4/12 (33.3)   |
| Subconjunctival                 | 7/23 (30.4)                       | 4/7 (57.1)           | 3/7 (42.9)    |
| **Focal therapy**              |                                   |                      |               |
| Diode laser                    | 13/23 (56.5)                      | 7/13 (53.8)          | 5/13 (38.5)   |
| Green laser                    | 10/23 (43.5)                      | 4/10 (40.0)          | 6/10 (60.0)   |
| Cryotherapy                    | 12/23 (52.2)                      | 7/12 (58.3)          | 7/12 (58.3)   |
| Brachytherapy                  | 9/23 (39.1)                       | 4/9 (44.4)           | 5/9 (55.6)    |
| **Treatment of advanced disease** |                                 |                      |               |
| Enucleation surgery            | 21/23 (91.3)                      | 12/21 (57.1)         | 20/21 (95.2)  |
| Abbreviation: EUA, examination under anesthesia.
present at 15 (65.2%) institutions, 12 (80.0%) of which held primary off-site appointments.

The association between ophthalmic or oncology resources and the tier classification system was analyzed. Statistically significant differences were found regarding availability of ophthalmologists, clinical nurse coordinators, ophthalmic supportive staff, occupational therapy, ophthalmic ultrasound, diode laser, cryotherapy, intravitreal chemotherapy, and subconjunctival chemotherapy ($P < .001$; Table 3). Other individual resources showed no statistically significant differences across tiers. Several oncology resources were robustly present across all tiers, such as pediatric oncologists, systemic chemotherapy, magnetic resonance imaging (MRI), lumbar puncture, bone marrow aspiration, and cytospin. Ophthalmologic resources with a high prevalence across all tiers were examination under anesthesia, fundus camera, indirect ophthalmoscopy, and pathology. However, resources such as a genetics, brachytherapy, and intra-arterial chemotherapy were proportionally similar across all tiers, but the overall availability of these resources was diminished, with only five, nine, and six centers reporting access to the resource, respectively.

**DISCUSSION**

A clear understanding of retinoblastoma-specific capacity has been lacking within the Eastern Mediterranean region. To our knowledge, this assessment represents the first comprehensive, resource-based survey dedicated to identifying capacity in a region for management of a specific pediatric cancer that requires multidisciplinary care. The novelty and specificity of responses provide informed recommendations with a degree of confidence for targeted intervention to improve the management of patients with retinoblastoma within the region.

Centralization of resources and cohesive multidisciplinary teams remain the primary gaps in patient care. All 23 POEM institutions had at least one pediatric oncologist; however, only 15 institutions had an ophthalmologist available. Of these 15 ophthalmologists, 12 had primary practices off site. This creates a disparity between oncologic and ophthalmologic care and indicates that patients with retinoblastoma are being treated at oncology units where ophthalmology may not be primarily available. The decentralized services place an additional travel burden on families and may impact rates of abandonment of therapy.

The partnership between pediatric oncology and ophthalmology is critical to the successful management of patients with retinoblastoma. The lack of ophthalmologists and ophthalmic infrastructure identified in this survey indicates a disparity between these subspecialties. This was noted by the comparison showing a median on-site availability of seven ophthalmology resources compared with 17.5 oncology resources (Tables 1 and 2). Although ophthalmic resources can have an aggregate cost of approximate US$250,000, consortium or in-bulk purchasing can mitigate overall costs and begin a network of collaboration in the region to overcome this disparity.

Building disease-specific expertise can overcome limited resources and centralize care. Elzomor et al. showed improved patient outcomes after implementation of multidisciplinary care and protocol-based treatment in Egypt. Improved outcomes included a decrease in mean time between enucleation and diagnosis, an increase in length of optic nerve obtained surgically, and an increase in the probability of survival. There is abundant literature correlating improved outcomes to centralized services and increased patient volume, such as centralization of pediatric neuro-oncology care leading to greater tumor resections with fewer complications, lower ventricular shunt failures, and lower mortality after craniotomy. Centralization of retinoblastoma care could similarly improve surgical outcomes such as a longer length of optic nerve resected during enucleation and familiarization with indications and use of focal eye-sparing modalities, such as laser, cryotherapy, and plaque brachytherapy. Centralized hospitals have also proven to be more cost effective because pediatric oncology resources can be used to treat all cancers and needed ophthalmic infrastructure can be used
### TABLE 3. Ophthalmic and Basic Oncologic Resources by Tier

| Resource                        | Tier 1 (n = 6) | Tier 2 (n = 12) | Tier 3 (n = 5) | P     |
|---------------------------------|----------------|-----------------|----------------|-------|
| **Key personnel**               |                |                 |                |       |
| Ophthalmologist                 | 0 (0.0)        | 10 (83.3)       | 5 (100.0)      | <.001*|
| Pediatric oncologist            | 6 (100.0)      | 12 (100.0)      | 5 (100.0)      | NA    |
| Radiation oncologist            | 3 (50.0)       | 9 (75.0)        | 5 (100.0)      | .092  |
| Pathologist                     | 4 (66.7)       | 11 (91.7)       | 5 (100.0)      | .186  |
| Geneticist                      | 0 (0.0)        | 2 (16.7)        | 1 (20.0)       | NA    |
| Clinical nurse coordinator      | 0 (0.0)        | 4 (33.3)        | 4 (80.0)       | .009* |
| **Supportive care staff**       |                |                 |                |       |
| Ophthalmic supportive staff     | 0 (0.0)        | 6 (50.0)        | 4 (80.0)       | .013* |
| Vision rehabilitation           | 0 (0.0)        | 2 (16.7)        | 1 (20.0)       | .407  |
| Audiologist                     | 0 (0.0)        | 3 (25.0)        | 3 (60.0)       | .040* |
| Nursing staff                   | 6 (100.0)      | 10 (83.3)       | 5 (100.0)      | 1.000 |
| Pharmacist                      | 6 (100.0)      | 7 (58.3)        | 5 (100.0)      | 1.000 |
| Occupational therapist          | 0 (0.0)        | 2 (16.7)        | 4 (80.0)       | .004* |
| Psychologist                    | 4 (66.7)       | 6 (50.0)        | 5 (100.0)      | .365  |
| Program data management         | 0 (0.0)        | 3 (25.0)        | 2 (40.0)       | .156  |
| Palliative care                 | 1 (16.7)       | 7 (58.3)        | 4 (80.0)       | .042* |
| **Diagnostics/staging**         |                |                 |                |       |
| Examination under anesthesia    | 4 (66.7)       | 12 (100.0)      | 5 (100.0)      | .099  |
| RetCam or fundus camera          | 3 (50.0)       | 10 (83.3)       | 4 (80.0)       | .322  |
| Ophthalmic ultrasound           | 3 (50.0)       | 12 (100.0)      | 5 (100.0)      | .017* |
| Indirect ophthalmoscope         | 4 (66.7)       | 12 (100.0)      | 5 (100.0)      | .099  |
| Pathology for processing an enucleated eye | 5 (83.3) | 12 (100.0) | 5 (100.0) | .478  |
| Access to genetic/molecular testing | 2 (33.3) | 6 (50.0) | 3 (60.0) | .557  |
| MRI                             | 5 (83.3)       | 12 (100.0)      | 5 (100.0)      | .478  |
| Lumbar puncture                 | 6 (100.0)      | 12 (100.0)      | 5 (100.0)      | NA    |
| Bone marrow aspiration          | 6 (100.0)      | 12 (100.0)      | 5 (100.0)      | NA    |
| CSF cytospin                    | 6 (100.0)      | 10 (83.3)       | 5 (100.0)      | 1.000 |
| **Focal therapy**               |                |                 |                |       |
| Green laser (532 nm)            | 1 (16.7)       | 5 (45.5)        | 4 (80.0)       | .071  |
| Diode laser (810 nm)            | 1 (16.7)       | 7 (63.6)        | 5 (100.0)      | .006* |
| Cryotherapy                     | 1 (16.7)       | 6 (54.5)        | 5 (100.0)      | .007* |
| Brachytherapy                   | 0 (0.0)        | 6 (54.5)        | 3 (60.0)       | .067  |
| **Chemotherapy**                |                |                 |                |       |
| Carboplatin                     | 6 (100.0)      | 11 (100.0)      | 5 (100.0)      | NA    |
| Vincristine                     | 6 (100.0)      | 11 (100.0)      | 5 (100.0)      | NA    |
| Etoposide                       | 6 (100.0)      | 11 (100.0)      | 5 (100.0)      | NA    |
| Topotecan                       | 5 (83.3)       | 8 (72.7)        | 4 (80.0)       | 1.000 |
| Melphalan                       | 3 (50.0)       | 8 (72.7)        | 5 (100.0)      | .098  |
| Doxorubicin                     | 6 (100.0)      | 11 (100.0)      | 4 (80.0)       | .227  |
| Cyclophosphamide                | 6 (100.0)      | 11 (100.0)      | 5 (100.0)      | NA    |
| Other anthracyclines            | 5 (83.3)       | 10 (90.9)       | 4 (80.0)       | 1.000 |

(Continued on following page)
to care for a greater number of patients.11 Al-Haddad et al15 increased patient volume from 20 patients between 2002 and 2011 to 52 patients between 2012 and 2017 by establishing a centralized service with increased referral from neighboring countries. In the case of our assessment, centers within the same city or country should identify one center to treat retinoblastoma and refer accordingly. Centralization, however, does come with a cost because it places a greater treatment burden on patients and families by increasing the distances traveled for care.16

Enucleation by a skilled ophthalmologist can cure most patients with localized, unilateral intraocular disease and should remain the standard of care when stringent follow-up is not guaranteed.17 In addition, excellent cosmesis is possible when orbital implants and protheses are available. On the basis of the assessed resource gaps, enucleation is the only available curative treatment in 13 centers as a result of lack of available of eye-sparing therapies.18,20 However, enucleation refusal is particularly common in LMICs, especially in contrast to high-income countries,20 as a result of social stigma, lack of support for visually impaired, belief in alternative medicine, religious or parental beliefs, and cultural contexts.20 Inability to offer complete cosmetic rehabilitation can further exacerbate enucleation refusal in the 30% of centers that reported limited or no access to orbital implants and 31% of centers that reported limited or no access to ocular prostheses. Induction chemotherapy can also be used as a strategy to facilitate enucleation in LMICs when parents are reluctant to proceed at diagnosis.16 Addressing these challenges in the East and Mediterranean regions may enhance the ability for curative management in patients who require enucleation.

Ophthalmology availability and training shortages are not limited to the East and Mediterranean. A global survey conducted by the International Council of Ophthalmology revealed an average of 3.7 ophthalmologists per million in low-income countries, as opposed to an average of 76.2 ophthalmologists per million in high-income countries.21 This may affect our findings as to why ophthalmic resources, specifically focal therapy and local delivery of chemotherapy, were viewed with less confidence across the region in comparison with oncologic resources. Education through regional fellowships, specifically ocular oncology, is required to build retinoblastoma-specific expertise that is often sparingly included in general ophthalmology residencies.22,24 Le et al23 evaluated Canadian ophthalmology residency programs and found that ocular oncology represented one of the least number of days spent in rotation (<60 days, compared with >124 days for pediatric ophthalmology), and only 45% of residents assisted in the required five retinoblastoma enucleation surgeries throughout their training. Our assessment identified only two separate ocular oncology fellowships, one in Jordan and one in Egypt. Utilization of these programs could allow for expansion of retinoblastoma care and collaboration across the region.

Telemedicine offers an additional avenue for education. Telemedicine has proved successful in improving the survival of children with pediatric cancer by pairing experienced centers with those with less experience.24 A joint venture between King Hussein Cancer Center in Amman, Jordan, and St Jude Children’s Research Hospital established a multidisciplinary team, invested in ophthalmic

| Resource | Tier 1 (n = 6) | Tier 2 (n = 12) | Tier 3 (n = 5) | P |
|----------|---------------|----------------|---------------|---|
| Chemotherapy delivery<sup>b</sup> | | | | |
| Intravitreal | 0 (0.0) | 7 (63.6) | 5 (100.0) | <.001<sup>a</sup> |
| Intra-arterial | 0 (0.0) | 4 (36.4) | 2 (40.0) | .188 |
| Subconjunctival | 0 (0.0) | 3 (27.3) | 4 (80.0) | .008<sup>a</sup> |
| Systemic | 6 (100.0) | 11 (100.0) | 5 (100.0) | NA |
| Advanced disease treatment<sup>b</sup> | | | | |
| Enucleation surgery | 5 (83.3) | 11 (100.0) | 5 (100.0) | NA |
| Orbital implant | 5 (83.3) | 11 (100.0) | 5 (100.0) | .500 |
| Orbital prostheses | 4 (66.7) | 11 (100.0) | 5 (100.0) | .108 |
| EBRT | 3 (50.0) | 10 (90.9) | 5 (100.0) | NA |
| High-dose chemotherapy | 4 (66.7) | 11 (100.0) | 5 (100.0) | NA |
| BMT | 2 (33.3) | 7 (63.6) | 5 (100.0) | NA |
| ASCR | 4 (66.7) | 8 (72.7) | 4 (80.0) | NA |

Abbreviations: ASCR, autologous stem-cell rescue; BMT, bone marrow transplantation; CSF, cerebrospinal fluid; EBRT, external-beam radiation therapy; MRI, magnetic resonance imaging; NA, not available.

<sup>a</sup>Statistically significant, P < .05.

<sup>b</sup>One tier 2 respondent missing.
Stratification of survey respondents was based on ophthalmic resources because all centers had basic pediatric oncology infrastructure. Thus, diagnostics including MRI and therapeutics such as systemic chemotherapy, key components of a pediatric cancer unit, did not differentiate across tiers.26 However, palliative care, which is more specialized, was increased at centers with more specialized resources (among tier 3 centers compared with tier 1 and 2 centers; Table 3). Palliative care has only recently been incorporated into the landscape of pediatric oncology and can be restricted as a result of financial constraints, opioid availability, and lack of recognition of palliative care as a necessary subspecialty in LMICs.27 It is desirable that palliative care would be available across all tiers given the increased likelihood of advanced disease at diagnosis in LMICs.18-20

Aims and guidelines for each tier can be developed that prioritize first the life of the child, followed by ocular salvage and then vision. Chantada et al6 published recommendations for graduated-intensity guidelines for the treatment of retinoblastoma in developing countries, which can contribute to improved patient outcomes.28 Because of the unavailability of an ophthalmologist to treat retinoblastoma, the primary objective of tier 1 centers should be prompt referral of identified leukocoria. Primary care providers and families must learn to recognize the leukocoria, or white pupil, the most common presenting symptom of retinoblastoma. An integrated regional network can lead to prompt referral of these patients to a multidisciplinary center for management. An important step in this process is educational programs. Example campaigns in Honduras linked education regarding leukocoria to vaccinations, reducing the incidence of extraocular disease at diagnosis by 38%.29 The six identified tier 1 centers were either general children’s hospital or general oncology hospitals. Because of the nature of the question, a respondent indicating “no ophthalmologist available to treat retinoblastoma,” does not exclude the possibility of having an in-house ophthalmologist. Tier 1 centers may have an ophthalmologist, especially at the general children’s hospitals. In such a case, the primary objective should be early diagnosis and referral. We should emphasize that early diagnosis in this setting pertains to intraocular disease without the manifestations of inflammation, buphthalmos, and proptosis.

Tier 2 centers represented the largest number of respondents (n = 12). Tier 2 centers can treat advanced disease by primary enucleation (with a pathologist to evaluate an enucleated eye to determine risk and need for adjuvant chemotherapy after surgery) or defer enucleation until chemotherapy has been given. Neoadjuvant chemotherapy may be required to reduce buphthalmos or allow time for the parents to accept surgical recommendations.25-26 Buphthalmos is present in two thirds of patients with retinoblastoma at presentation in LMICs,31 and enucleation holds a greater risk of globe rupture with disease spread.

Five respondents were identified as tier 3 centers possessing comprehensive oncology and ophthalmology resources as well as fully integrated multidisciplinary teams. Conservative eye-sparing therapy is a principal objective for tier 3 centers for patients amendable to chemoreduction with focal consolidation, especially when follow-up is likely and in the case of bilateral disease. These tier 3 centers can thus become a hub for patient care and retinoblastoma education. This was modeled by the Children’s Cancer Institute in Beirut, Lebanon, which increased referrals from other centers in Lebanon, Syria, and Iraq after establishment of a program in 2012.15 Regional hubs, as opposed to remote partners, are more accessible and apt to address cultural barriers, facilitating care of the child. These centers can also build educational capacity throughout the region by identifying themselves as centers of excellence, serving as leaders in the management of retinoblastoma in the region.

This assessment was subject to limitations. First, there was a low response rate of 32% from POEM member countries at the time of distribution. Although this sample size is good for the methodology, 68% of centers still failed to respond. Second, we must recognize the inherent bias that comes along with any survey instrument. This includes the bias of self-reporting answers and self-interpretation of questions. Investigating resource data in relation to patient outcomes is of useful inquiry for future studies.

This assessment revealed common themes related to the treatment of pediatric cancer, more specifically retinoblastoma, in LMICs, including decentralization of care, limited subspecialty expertise, and lack of available multidisciplinary care. Resource disparities warrant targeted intervention in the Eastern Mediterranean region to advance the management of retinoblastoma throughout the region. Such strategies include centralization of care, education through regional fellowships, recruitment of multidisciplinary teams, and establishment of regional centers of excellence.
CORRESPONDING AUTHOR
Matthew W. Wilson, MD, Hamilton Eye Institute, Department of Ophthalmology, University of Tennessee, 930 Madison Ave, Room 476, Memphis, TN 38163; e-mail: mwilson5@uthsc.edu.

AUTHOR CONTRIBUTIONS
Conception and design: Michala Burges, Ibrahim Qaddoumi, Rachel C. Brennan, Carlos Rodriguez-Galindo, Sima Jeha, Matthew W. Wilson
Financial support: Matthew W. Wilson
Administrative support: Lisa Krull
Provision of study materials or patients: Sima Jeha
Collection and assembly of data: Michala Burges, Ibrahim Qaddoumi, Natasha Sahr, Matthew W. Wilson
Data analysis and interpretation: All authors
Manuscript writing: All authors
Final approval of manuscript: All author
Accountable for all aspects of the work: All authors

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/wwc or ascopubs.org/go/site/misc/authors.html.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Natasha Sahr
Employment: Novartis
Honoraria: GDIT
Consulting or Advisory Role: Microport Orthopedics
Travel, Accommodations, Expenses: See comments

No other potential conflicts of interest were reported.

ACKNOWLEDGMENT
This study was facilitated by the Pediatric Oncology East and Mediterranean (POEM) network and its central office located at the American University of Beirut, Beirut, Lebanon. We acknowledge the POEM group for its support and the individual POEM institutions that provided data responses.

REFERENCES
1. Pizzo PA, Poplack DG (eds): Retinoblastoma, in Principles and Practice of Pediatric Oncology. Philadelphia, PA, Lippincott, Williams and Wilkins, 2006, pp 699-715
2. Canturk S, Qaddoumi I, Khetan V, et al: Survival of retinoblastoma in less-developed countries impact of socioeconomic and health-related indicators. Br J Ophthalmol 94:1432-1436, 2010
3. Shields CL, Shields JA: Recent developments in the management of retinoblastoma. J Pediatr Ophthalmol Strabismus 36:8-18, 1999
4. Gallie BL, Zhao J, Vandezande K, et al: Global issues and opportunities for optimized retinoblastoma care. Pediatr Blood Cancer 49:1083-1090, 2007 (suppl 7)
5. Rodriguez-Galindo C, Friedrich P, Alcasabas A, et al: Toward the cure of all children with cancer through collaborative efforts: Pediatric oncology as a global challenge. J Clin Oncol 33:3065-3073, 2015
6. Chantada G, Luna-Fineman S, Sitorus RS, et al: SIOP-PODC recommendations for graduated-intensity treatment of retinoblastoma in developing countries. Pediatr Blood Cancer 60:719-727, 2013
7. SurveyMonkey: Retinoblastoma resource follow-up. https://www.surveymonkey.com/r/LNF32B
8. World Bank: World Bank analytical classifications. World Development Indicators, The World Bank Group, 2018. https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups
9. Eltzor H, Taha H, Nour R, et al: A multidisciplinary approach to improving the care and outcomes of patients with retinoblastoma at a pediatric cancer hospital in Egypt. Ophthalmic Genet 38:345-351, 2017
10. Qaddoumi I: Centralized services and large patient volumes are clinical necessities for a better outcome in pediatric brain tumors. Childs Nerv Syst 32:591-592, 2016
11. Qaddoumi I, Usai E, Diez B, et al: Web-based survey of resources for treatment and long-term follow-up for children with brain tumors in developing countries. Childs Nerv Syst 27:1957-1961, 2011
12. Albright AL, Spoto R, Holmes E, et al: Correlation of neurosurgical subspecialization with outcomes in children with malignant brain tumors. Neurosurgery 47:879-885, 2000
13. Smith ER, Butler WE, Barker FG 2nd: Craniotomy for resection of pediatric brain tumors in the United States, 1988 to 2000: Effects of provider caseloads and progressive centralization and specialization of care. Neurosurgery 54:553-563, 2004
14. Berry JG, Hall MA, Sharma V, et al: A multi-institutional, 5-year analysis of initial and multiple ventricular shunt revisions in children. Neurosurgery 62:445-453, 2008
15. Al-Haddad C, Bashour Z, Farah L, et al: Establishment of a formal program for retinoblastoma: Feasibility of clinical coordination across borders and impact on outcome. Pediatr Blood Cancer 66:e27959, 2019
16. Sitzenberg KB, Sigurdson ER, Egleston BL, et al: Centralization of cancer surgery: Implications for patient access to optimal care. J Clin Oncol 27:4671-4678, 2009
17. Wilson MW, Rodriguez-Galindo C (eds): Retinoblastoma in developing countries, in Retinoblastoma. New York, NY, Springer, 2010, pp 156-162
18. Sitorus RS, Moll AC, Suhardjono S, et al: The effect of therapy refusal against medical advice in retinoblastoma patients in a setting where treatment delays are common. Ophthalmic Genet 30:31-36, 2009
19. Gupta R, Vemuganti GK, Reddy VA, et al: Histopathologic risk factors in retinoblastoma in India. Arch Pathol Lab Med 133:1210-1214, 2009
20. Olteanu C, Dimaras H: Enculeation refusal for retinoblastoma: A global study. Ophthalmic Genet 37:137-143, 2016
21. Resnikoff S, Lansings VC, Washburn L, et al: Estimated number of ophthalmologists worldwide (International Council of Ophthalmology update): Will we meet the needs? Br J Ophthalmol 104:588-592, 2020
22. Zhou AW, Noble J, Lam WC: Canadian ophthalmology residency training: An evaluation of resident satisfaction and comparison with international standards. Can J Ophthalmol 44:540-547, 2009
23. Le K, Bursztyn L, Rootman D, et al: National survey of Canadian ophthalmology residency education. Can J Ophthalmol 51:219-225, 2016

1538 © 2020 by American Society of Clinical Oncology
24. Qaddour I, Nawaiseh I, Mehyar M, et al: Team management, twinning, and telemedicine in retinoblastoma: A 3-tier approach implemented in the first eye salvage program in Jordan. Pediatr Blood Cancer 51:241-244, 2008
25. Al-Nawaiseh I, Jammal HM, Khader YS, et al: Retinoblastoma in Jordan, 2003-2013: Ocular survival and associated factors. Ophthalmic Epidemiol 21:406-411, 2014
26. Stefan D, Rodriguez-Galindo C (eds): Palliative and supportive care, in Pediatric Hematology-Oncology in Countries with Limited Resources. New York, NY, Springer, 2014, pp 139-152
27. Webster R, Lacey J, Quine S: Palliative care: A public health priority in developing countries. J Public Health Policy 28:28-39, 2007
28. Baskin JL, Lezcano E, Kim BS, et al: Management of children with brain tumors in Paraguay. Neuro-oncol 15:235-241, 2013
29. Leander C, Fu LC, Peña A, et al: Impact of an education program on late diagnosis of retinoblastoma in Honduras. Pediatr Blood Cancer 49:817-819, 2007
30. Radhakrishnan V, Kashyap S, Pushker N, et al: Outcome, pathologic findings, and compliance in orbital retinoblastoma (International Retinoblastoma Staging System stage III) treated with neoadjuvant chemotherapy: A prospective study. Ophthalmology 119:1470-1477, 2012
31. Abramson DH, Frank CM, Susman M, et al: Presenting signs of retinoblastoma. J Pediatr 132:505-508, 1998